Grey Hair May Signal Protection Against Melanoma

In a laboratory in Tokyo, scientists have been watching something striking: when certain hair cells are damaged, they do not attempt to repair themselves.

They disappear.

Far from being a minor biological detail, this cellular “giving up” may help explain a familiar sight in the mirror: hair turning grey or white over time.

Grey hair as a sign of internal defence

Research from the University of Tokyo’s Institute of Medical Science, published in Nature Cell Biology in 2025, puts forward a surprising interpretation: in many cases, grey hair may be a visible sign of a protective system against skin cancer.

The study centres on pigment stem cells, known as McSCs, which reside in the hair follicle and generate melanocytes, the cells responsible for hair colour. When the DNA in these cells sustains serious damage, they do not keep dividing and risk becoming a tumour; instead, they follow an irreversible path.

Scientists suggest that when hair loses pigment and turns grey, it may reveal a silent process of cellular “self-sacrifice” against cancer.

This process has been termed “senodifferentiation”: the damaged cell is driven into terminal differentiation before subsequently disappearing. The cost is a loss of colour. The likely benefit is a reduced risk of melanoma, one of the most aggressive forms of skin cancer.

How this protective mechanism works

The role of pigment stem cells

Within the hair follicle, McSCs exist in a tightly controlled environment called the “niche”. There, chemical signals determine whether they remain dormant, multiply or become pigment-producing cells.

When they experience major DNA damage, such as double-strand breaks, a pathway well known in oncology comes into play: the p53–p21 axis. This system is already recognised as a form of emergency brake against tumours in various body tissues.

In hair, researchers found in mice that, under stresses such as X-ray exposure, damaged McSCs stop renewing themselves and are pushed into senodifferentiation. Across successive hair-growth cycles, the visible outcome is the appearance of grey or white hairs.

When the p53–p21 pathway is activated, the cell agrees to “die as pigment” rather than “live as a potential cancer”.

The experiments used real-time cell-tracking methods and gene-expression analysis, enabling the researchers to follow the fate of these cells throughout hair-growth cycles under different forms of stress.

When the system fails: carcinogens enter the picture

The research also revealed the other side of the process: in some circumstances, this biological brake can be undermined. When cells are exposed to carcinogenic agents, such as the chemical DMBA or UVB radiation, the protective pathway can be blocked even when DNA damage is clearly present.

In these situations, rather than sacrificing themselves, McSCs retain their ability to multiply. They carry genetic lesions yet remain alive within the follicle, creating favourable conditions for the emergence of pre-melanoma clones.

A key player in this diversion is KITL, the KIT ligand, a protein produced by both the skin and the follicle structure itself. It activates the KIT signalling pathway, which in turn weakens the p53–p21 axis. Put simply, the instruction to “stop and leave the stage” is drowned out by a signal telling the cell to “keep growing”.

• With high KITL levels: more damaged cells survive, with a greater risk of melanocytic lesions.
• With low KITL levels: greying increases, but the likelihood of melanoma formation falls.

Genetically modified mice confirmed this pattern. Animals with excess KITL retained damaged McSCs after exposure to carcinogens and developed more changes consistent with the early stages of tumours. Those unable to produce KITL in the follicle region became greyer, but had a lower incidence of tumour lesions.

Ageing: when the cell environment also becomes unwell

The Japanese study did not examine cells in isolation alone. Researchers also investigated their surrounding “neighbourhood” - the niche - and how it changes with age.

As ageing progresses, the niche becomes less effective. In older mice, scientists identified reduced p53 pathway activity in skin stem cells that coexist with McSCs. Alongside this decline, some molecules involved in the DNA-damage response were also present in lower amounts.

Interestingly, the production of factors such as KITL may decrease, but this does not automatically mean greater protection. A combination of faulty signals, chronic inflammation and disruption of other metabolic pathways, including the arachidonic acid pathway, changes how cells interpret stress.

In this setting, grey hair is no longer such a direct picture of this cellular “clean-up” mechanism. In older people, whether greying appears may reflect a complex mix of genetics, environment, carcinogen exposure and the niche’s capacity to respond.

Grey hair and cancer: two outcomes tied to the same choice

The authors describe this process as the “antagonistic fates” of pigment stem cells. Under stress, the same cell may take one of two routes: it may contribute to visible hair ageing, or it may give rise to a focus of skin cancer.

On one side is a hair that loses its colour because the cell has stepped out of the picture. On the other is a hair that remains pigmented, while concealing a nearby group of persistent mutated cells.

The research suggests that the body is constantly negotiating between ageing a little more while facing less cancer risk, or preserving a youthful appearance at the cost of looser cellular surveillance.

This perspective helps explain why some people develop melanoma without a notable history of intense sun exposure, while others turn grey very early and never develop skin cancer. The way this “decision-making system” is programmed in each body makes a difference.

What this means in practice for the reader

Having grey hair does not suddenly become a walking medical test. However, the study reinforces several useful points:

• greying may partly reflect the body’s ability to eliminate problematic cells effectively;
• chronic exposure to carcinogens, including intense unprotected sunlight or certain chemicals, tends to undermine these natural brakes;
• healthy ageing involves more than “avoiding wrinkles”; it also means protecting the quality of the signals that guide cells.

For people who already have plenty of white hairs, it is worth dropping the automatic association between greying and a “weak body”. In many cases, grey hair may tell the story of a defence system that has worked hard over the years.

Conversely, someone whose hair is still dark at 60 is not automatically at an advantage. If the signalling that should push damaged cells out of the system is compromised, this preserved appearance may come with a less watchful cellular environment.

Key concepts about grey hair, McSCs and melanoma

Several terms from the study help organise these ideas:

• Pigment stem cell (McSC): a “parent” cell that gives rise to melanocytes, which produce melanin and hair colour;
• p53–p21 pathway: a set of genes that acts as a brake on cells with damaged DNA;
• Senodifferentiation: a process in which a damaged cell is pushed into a final state, with no possibility of dividing again;
• KIT/KITL: a signalling system that promotes survival and growth, and which can interfere with the p53 brake in certain settings;
• Niche: the microenvironment in which stem cells live and receive signals that determine what they should do.

Picture a miniature hair salon inside every follicle. McSCs are the colour specialists. The p53 system is the safety manager, ready to remove any worker who turns up drunk on mutations. KITL is the persistent client asking for “just one more colouring”, urging the team to carry on working even when exhausted. Over time, if management fails and the intrusive client has more authority than everyone else, the risk of disaster rises.

This metaphor illustrates why researchers are already considering therapies that could reinforce this molecular “management”. Rather than only attacking established tumours, future treatments might encourage senodifferentiation in suspicious cells, reducing melanoma risk at very early stages, before any mark appears on the skin.